Financial giants have made a conspicuous bullish move on Novo Nordisk. Our analysis of options history for Novo Nordisk (NYSE:NVO) revealed 8 unusual trades.
Delving into the details, we found 50% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $1,977,143, and 5 were calls, valued at $222,954.
Predicted Price Range
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $85.0 to $135.0 for Novo Nordisk over the last 3 months.
Volume & Open Interest Development
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Novo Nordisk's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Novo Nordisk's substantial trades, within a strike price spectrum from $85.0 to $135.0 over the preceding 30 days.
Novo Nordisk 30-Day Option Volume & Interest Snapshot
Largest Options Trades Observed:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NVO | PUT | TRADE | NEUTRAL | 09/19/25 | $47.95 | $45.9 | $47.0 | $135.00 | $1.8M | 1 | 400 |
| NVO | CALL | TRADE | NEUTRAL | 01/15/27 | $22.35 | $21.45 | $21.85 | $85.00 | $80.8K | 386 | 37 |
| NVO | PUT | TRADE | BULLISH | 01/10/25 | $28.25 | $26.65 | $27.15 | $115.00 | $65.1K | 0 | 24 |
| NVO | CALL | TRADE | BEARISH | 01/15/27 | $12.85 | $12.1 | $12.35 | $110.00 | $45.6K | 642 | 0 |
| NVO | CALL | SWEEP | BULLISH | 01/17/25 | $4.6 | $4.5 | $4.6 | $85.00 | $41.3K | 1.4K | 107 |
About Novo Nordisk
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
In light of the recent options history for Novo Nordisk, it's now appropriate to focus on the company itself. We aim to explore its current performance.
Novo Nordisk's Current Market Status
- Trading volume stands at 354,286, with NVO's price up by 0.03%, positioned at $87.68.
- RSI indicators show the stock to be may be oversold.
- Earnings announcement expected in 40 days.
What Analysts Are Saying About Novo Nordisk
1 market experts have recently issued ratings for this stock, with a consensus target price of $105.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access.* Consistent in their evaluation, an analyst from BMO Capital keeps a Outperform rating on Novo Nordisk with a target price of $105.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Novo Nordisk options trades with real-time alerts from Benzinga Pro.
